ARN-6039 is under clinical development by Signalexis and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome). According to GlobalData, Phase I drugs for Neuromyelitis Optica (Devic’s Syndrome) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ARN-6039’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ARN-6039 overview

BOS-172767 (ARN-6039) is under development for the treatment of solid tumor, melanoma, pancreatic cancer, multiple sclerosis, psoriasis and neuromyelitis optica (NMO). It is administered through oral route as a capsule and tablet. It is a new chemical entity. The drug candidate targets retinoic acid-related orphan nuclear receptor gamma t (RORgt). It is developed based on the Fragment-Field Drug Design (FFDD) based technology.

Signalexis overview

Signalexis is a biotechnology company engaged in research and development of novel small molecule therapeutics for the treatment of solid tumors. The company is headquartered in American Fork, Utah, the US.

For a complete picture of ARN-6039’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.